Cadence Capital Management LLC Takes $689,000 Position in Aclaris Therapeutics Inc (NASDAQ:ACRS)

Cadence Capital Management LLC acquired a new stake in Aclaris Therapeutics Inc (NASDAQ:ACRS) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 26,688 shares of the biotechnology company’s stock, valued at approximately $689,000. Cadence Capital Management LLC owned approximately 0.09% of Aclaris Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. UBS Group AG lifted its position in Aclaris Therapeutics by 60.4% in the 1st quarter. UBS Group AG now owns 4,462 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 1,681 shares in the last quarter. Alps Advisors Inc. lifted its position in Aclaris Therapeutics by 7.7% in the 2nd quarter. Alps Advisors Inc. now owns 24,129 shares of the biotechnology company’s stock valued at $654,000 after acquiring an additional 1,718 shares in the last quarter. Alliancebernstein L.P. lifted its position in Aclaris Therapeutics by 24.0% in the 1st quarter. Alliancebernstein L.P. now owns 9,300 shares of the biotechnology company’s stock valued at $277,000 after acquiring an additional 1,800 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in Aclaris Therapeutics by 26.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the biotechnology company’s stock valued at $250,000 after acquiring an additional 1,900 shares in the last quarter. Finally, TD Asset Management Inc. lifted its position in Aclaris Therapeutics by 15.6% in the 2nd quarter. TD Asset Management Inc. now owns 17,100 shares of the biotechnology company’s stock valued at $464,000 after acquiring an additional 2,304 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts recently commented on the stock. BidaskClub raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Zacks Investment Research raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price objective on the stock in a research report on Tuesday, October 10th. Cantor Fitzgerald set a $50.00 price objective on shares of Aclaris Therapeutics and gave the company a “buy” rating in a research report on Wednesday, October 4th. ValuEngine cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $39.00 price objective on shares of Aclaris Therapeutics in a research report on Friday, September 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $39.20.

Shares of Aclaris Therapeutics Inc (ACRS) opened at $25.10 on Thursday. Aclaris Therapeutics Inc has a 52 week low of $21.32 and a 52 week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.23. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $2.00 million. analysts expect that Aclaris Therapeutics Inc will post -2.59 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://ledgergazette.com/2017/12/14/26688-shares-in-aclaris-therapeutics-inc-acrs-purchased-by-cadence-capital-management-llc.html.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply